An Open-Label, Mutlicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 7444 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Genentech
- 10 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2012 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.